Three Polaris biotechnology companies have recently made headlines for their strong business and research momentum.
First, despite a very difficult initial public offering market, Polaris-backed GI Dynamics recently raised approximately $85 million (USD), completing the largest IPO so far this year on the Australian market. The company began trading on the Australian Securities
Exchange last week. The strong support GI Dynamics received from investors is due to the commercial potential of the company’s lead product, EndoBarrier, as well as to the company’s consistent execution across its research, development, and commercialization plans.
Cerulean Pharma and Selecta Biosciences were also included in the FierceBiotech
2011 Fierce 15. This year’s Fierce 15 includes private life sciences companies “out to
do something truly exceptional”…with…”pioneering technology and innovative business models.”
Cerulean, founded in 2007, has already advanced its nanotechnology approach of packaging powerful chemotherapy drugs for release in targeted cells. The company has launched a randomized Phase II study for non-small cell lung cancer. Selecta, founded in 2008, is quickly marrying its combination of biodegradable polymer nanoparticles with
its synthetic vaccine particle platform. The company’s lead program, a nicotine vaccine for smoking cessation and relapse, will enter clinical trials in the fourth quarter of this year.
We agree with FierceBiotech that these two biotechnology companies are pursing important therapeutic paths, and like GI Dynamics, their management teams have maintained terrific scientific and business focus. It is exciting to recognize the accomplishments of these companies and the exceptional entrepreneurs leading them.